L-
asparaginase is a cardinal biotherapeutic
drug for treating
acute lymphoblastic leukemia, which is highly prevalent in children worldwide. In the current investigation, L-
asparaginase producing marine bacterial isolate, Bacillus australimaris NJB19 (MG734654), was observed to be producing extracellular
glutaminase free L-
asparaginase (13.27 ± 0.4 IU mL-1). Production of L-
asparaginase was enhanced by the Box-Behnken design approach that enumerated the significant variables affecting the
enzyme production. The optimum levels of the derived variables resulted in 2.8-fold higher levels of the
enzyme production (37.93 ± 1.06 IU mL-1). An 1146 bp L-
asparaginase biosynthetic gene of Bacillus australimaris NJB19 was identified and cloned in E. coli DH5α, fused with a
histidine tag. The in silico analysis of the
protein sequence revealed the presence of a
signal peptide and classified it as a type II L-
asparaginase. Toxic
peptide prediction disclosed no toxin domain in the
protein sequence, hence suggesting it as a non-toxic
protein. The secondary structure analysis of the
enzyme displayed a comparable percentage of alpha-helical and random coil structure, while 14.39% and 6.57% of
amino acid residues were composed of extended strands and beta-turns, respectively. The functional sites in the three-dimensional structural model of the
protein were predicted and interestingly had a few less conserved residues. Bacillus australimaris NJB19 identified in this study produces type-II L-
asparaginase, known for its high affinity for
asparagine and effectiveness against leukemic cells. Hence, these observations indicate the L-
asparaginase, thus obtained, as a potentially significant and novel therapeutic
drug.